Opko健康 OPK 深 沪
已收盘 10-09 16:00:00 美东时间
1.38
+0.010
+0.73%
华盛通- 最 高1.42
- 今 开1.38
- 成交量 109.36万股
- 最 低 1.37
- 昨 收 1.37
- 总市值 10.30亿
- 52周最高 1.75
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 0.9769
- 委 比 9.04%
- 总股本 7.46亿
- 历史最高 19.20
- 量 比 0.54
- 振 幅 3.65%
- 历史最低 0.8516
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Entera Bio Ltd. announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. With over 35 years of experience in global commercial leadership, Hamill joins Entera as it advances its late-stage clinical trials and prepares for the commercialization of EB613, an oral therapy for osteoporosis. Hamill previously served at Gilead Sciences and Amgen, leading multi-billion dollar franchises. Her expertise is expected ...
10-06 12:00
Opko Health Triggers Conversion of 2029 Convertible Notes
An announcement from Opko Health ( ($OPK) ) is now available. On October 1, 202...
10-03 04:29
Entera to Participate in Upcoming Fall Investor Conferences
Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in several fall investor conferences in 2026. The company focuses on developing oral peptide therapies for unmet medical needs using its proprietary N-Tab® technology. Its lead product, EB613, an oral PTH(1-34) tablet for osteoporosis, met Phase 2 endpoints. Entera also advances EB612 for hypoparathyroidism and other innovative therapies for obesity and rare conditions.
08-27 12:00
Opko Health Expands Royalty-Backed Long-Term Note Financing
Opko Health ( ($OPK) ) has shared an update. On August 13, 2026, OPKO Health am...
08-15 05:19
OPKO Health Issues Additional $125M Of Senior Secured Notes To KKR's HealthCare Royalty For Non-Dilutive Funding
The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement. The transaction provides OPKO with a...
08-13 21:20
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health expanded its financing with HealthCare Royalty, issuing an additional $125 million in senior secured notes. These notes are backed by mazdutide royalties and mature in 2044. The transaction provides non-dilutive capital while preserving long-term royalty upside. OPKO retains future royalty economics after capped payments of 1.5 times the funded amount. Mazdutide is commercialized in China by Innovent Biologics, with OPKO receiving roy...
08-13 13:15
Entera Q2 2026 earnings: Phase 3 preparation widened the loss
Entera Bio’s Q2 2026 earnings showed no revenue and a net loss of $7.3 million, versus $2.7 million a year earlier, while loss per share widened to $0.14 from $0.06. R&D expense rose to $3.2 million as the company prepared EB613 for a planned late-2026 Phase 3 start and advanced work under its OPKO collaboration. After quarter-end, Entera completed a $275 million private placement that it expects will fund the EB613 registrational program through
08-07 20:18
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera Bio Ltd. reported financial results and updates for Q2 2026, highlighting FDA alignment on a 12-month Phase 3 study for EB613, an oral anabolic tablet for postmenopausal osteoporosis. The company secured $275M in private placement led by BVF Partners to fund EB613's development through NDA submission. EB613's Phase 3 initiation is planned for late 2026, with topline data expected in H2 2028. Additionally, preclinical data for EB612, an ora...
08-07 20:05
OPKO Health Boosts Stake in Cocrystal Pharma Financing
Cocrystal Pharma ( ($COCP) ) has shared an announcement. On August 3, 2026, Coc...
08-03 19:48
